| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
TNF-alpha (Tumor Necrosis Factor alpha). TNF-alpha-IN-1 inhibits the binding of TNF-alpha to its receptor and downstream signaling.
|
|---|---|
| ln Vitro |
TNF-alpha-IN-1 is a TNF-alpha inhibitor. It inhibits the binding of TNF-alpha to its receptor and downstream signaling, resulting in reduced inflammation. The compound can be studied in research for cancers, heart disease, autoimmune disease, and infections.
|
| ln Vivo |
No specific in vivo activity data is available for TNF-alpha-IN-1. Based on its TNF-alpha inhibitory activity, it has potential for in vivo studies in models of inflammation, autoimmune disease, and cancer.
|
| Enzyme Assay |
In vitro assays for TNF-alpha-IN-1 typically involve measuring its ability to inhibit TNF-alpha binding to its receptor (TNFR1 or TNFR2) using ELISA or cell-based binding assays. Inhibition of downstream signaling (e.g., NF-kappaB activation, cytokine production) can be assessed in cells treated with TNF-alpha and the compound. IC50 values are determined from dose-response curves.
|
| Cell Assay |
The in vitro cellular activity of TNF-alpha-IN-1 is evaluated in cell lines or primary cells responsive to TNF-alpha. Cells are treated with the compound and stimulated with TNF-alpha, and downstream signaling (e.g., NF-kappaB activation, MAPK phosphorylation) and cytokine production are measured. The compound's ability to reduce inflammation and cell death is assessed.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for TNF-alpha-IN-1. For studying TNF-alpha inhibition in vivo, the compound would be administered via intraperitoneal injection or oral gavage in rodent models of inflammation, autoimmune disease (e.g., collagen-induced arthritis, IBD), or cancer. Endpoints would include disease severity, cytokine levels, and histopathology.
|
| ADME/Pharmacokinetics |
TNF-alpha-IN-1 has a molecular formula of C16H14ClN3O5 and a molecular weight of 363.75. Solubility: DMSO: 180 mg/mL (494.85 mM). Storage: powder at -20degC for 3 years. In vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for TNF-alpha-IN-1. As a research compound intended for laboratory use, standard safety precautions should be observed. No clinical toxicity studies have been reported.
|
| References | |
| Additional Infomation |
TNF-alpha-IN-1 (Compound I-7) is a TNF-alpha inhibitor that inhibits the binding of TNF-alpha to its receptor and downstream signaling. It can be studied in research for cancers, heart disease, autoimmune disease, and infections. It is not approved for clinical use.
|
| Molecular Formula |
C16H14CLN3O5
|
|---|---|
| Molecular Weight |
363.752462863922
|
| Exact Mass |
363.062
|
| CAS # |
444287-49-4
|
| PubChem CID |
10270102
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
718.6±60.0 °C at 760 mmHg
|
| Flash Point |
388.4±32.9 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
-0.66
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XRAYWKDMFVKUTJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14ClN3O5/c17-6-12(22)18-7-8-2-1-3-9-13(8)16(25)20(15(9)24)10-4-5-11(21)19-14(10)23/h1-3,10H,4-7H2,(H,18,22)(H,19,21,23)
|
| Chemical Name |
2-chloro-N-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]methyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~549.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (13.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (13.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7491 mL | 13.7457 mL | 27.4914 mL | |
| 5 mM | 0.5498 mL | 2.7491 mL | 5.4983 mL | |
| 10 mM | 0.2749 mL | 1.3746 mL | 2.7491 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
